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I.INTRODUCTION
Postoperative nausea and vomiting is often referred to as the “big, little problem” within the 
anesthesia world.  Postoperative nausea and vomiting, commonly abbreviated PONV, is defined as 
nausea and/or vomiting that occurs within 24 hours after surgery and can occur following general, 
regional, or local anesthesia. PONV has been a potential complication following surgery and anesthesia 
since the “ether” era. Although the incidence of PONV has decreased significantly from the 75%–80% 
occurrence rate at that time, it remains one of the most common complications postoperatively despite 
the numerous advancements in surgery and anesthesia.  The incidence of PONV can be as high as 80% 
following certain procedures like ENT& Laparoscopic surgeries. However, only 10% of post-surgical 
patients overall will experience PONV during the immediate postoperative period in the PACU (Post-
Anesthesia Care Unit),  while 30% will  experience PONV at some point during the initial  24-hour 
postoperative period. Additionally, it is important to note that, although PONV may last from minutes 
to hours and occurs most commonly during the first 24 hours postoperatively, it can actually persist for 
several days and is, therefore, not isolated to a problem occurring only in the immediate postoperative 
period.
 
II. AIM OF STUDY
To study the efficacy of oral Granisetron, a selective 5 HT 3 receptor 
antagonist, for the prevention of post operative vomiting after 
Adenotonsillectomy in children
III. PATHOPHYSIOLOGY OF POSTOPERATIVE NAUSEA 
AND VOMITING
Vomiting Center/ Chemo receptor Trigger Zone
The precise mechanism of PONV is not completely understood, however, the theory behind the 
occurrence of nausea and vomiting postoperatively is that it is caused by the stimulation of a variety of 
receptors located in the central nervous system and the gastrointestinal tract which subsequently 
activate a distinct area of the brain called the vomiting center.
The vomiting center is located in a region of the brain known as the nucleus tractus solitarius, 
which is situated in the lateral reticular formation of the fourth ventricle in the brainstem and controls 
vomiting through both direct and indirect stimulation. Impulses are transmitted by afferent fibers of 
both the sympathetic and parasympathetic nervous system to the vomiting center, whereby an emetic 
response is initiated. Impulses are sent to the vomiting center from four distinct areas, including 
a) the chemo receptor trigger zone (CTZ),
b)  higher cortical centers,
c)  the vestiblular apparatus of the middle ear, and 
d) the gastrointestinal tract. 
The nucleus tractus solitarius, or vomiting center, serves as the point of termination in the lower 
medulla for all visceral afferent nerve fibers and although vagal fibers predominate, fibers from 
the seventh and ninth cranial nerves and several spinal nerves terminate in this area .
Diagram Showing Location of Vomiting Center
 Pharyngeal stimulation, irritation or distension of the gut, distension of the renal pelvis, 
testicular injury, or cervical dilatation may lead to nausea and vomiting through direct stimulation of 
the vomiting center in the nucleus tractus solitarius
The vomiting center is indirectly stimulated by another major center known as the 
chemoreceptor trigger zone (CTZ). The CTZ is located in the brainstem in the area postrema, a 
spongiform body that protrudes into the fourth ventricle. The area postrema is highly vascularized and 
the vessels terminate in fenestrated capillaries surrounded by large perivascular spaces. The CTZ 
contains Adrenergic, cholinergic, histamine, dopamine, Serotonin, and opioid receptors. Because there 
is no effective blood-brain barrier in the area of the CTZ, it responds directly to chemical stimuli in the 
blood and cerebrospinal fluid through stimulation of its various receptors. The receptors in the CTZ 
play an important role in the transmission of impulses to the vomiting center .Another source of 
indirect stimulation to the vomiting center is movement, which can stimulate equilibrium receptors in 
the vestiblular apparatus of the middle ear followed by transmission of impulses via afferent fibers 
carried in cranial nerve VIII to the CTZ with subsequent transmission to the vomiting center. The 
vestiblular apparatus is unusual, however, in that it may also directly stimulate the vomiting center 
through these same afferent pathways. The cerebral cortex can directly stimulate the vomiting center 
through the transmission of psychic stimuli, such as noxious odors or tastes along with unpleasant 
visual stimuli.
 In addition, hypoxia, pain, and increased intracranial pressure directly stimulate the vomiting 
center by way of various afferent pathways from higher cortical areas. 
Hormonal influences have an additional impact on the vomiting center, whereby stimulation of 
α-Adrenergic receptors leads to vomiting due to the release of nor epinephrine, while β-Adrenergic 
receptor stimulation is associated with inhibition of the vomiting response. Other peptide hormones 
implicated in the incidence of nausea and vomiting include adreno corticotropic hormone (ACTH), 
vasopressin, human chorionic gonadotropin, angiotensin II, leu-enkephalin, met-enkepalin, 
cholecystokinin, insulin, gastrin, Serotonin, oxytocin, bombesin, thyrotopin-releasing hormone (TRH), 
peptide YY, neurotensin, and vasoactive intestinal peptide (VIP). Co-existing diseases of the heart, 
gastrointestinal tract, billiary tract, and genitourinary tract or distension of the gastrointestinal tract may 
stimulate the vomiting center via visceral afferent pathways. Specifically, the gastrointestinal tract, at 
the level of the small intestine, is a primary location of Serotonin receptors and when stimulated, these 
receptors send impulses through sympathetic and vagal afferent pathways to the vomiting center
Nausea/Retching/Vomiting
The act of vomiting can be divided into three phases including pre-ejection, ejection, and post-
ejection. The pre-ejection phase is marked by the symptoms of nausea including the autonomic signs of 
salivation, excessive swallowing, pallor, tachycardia, and tachypnea. 
Retching and vomiting comprise the ejection phase, while the post-ejection phase consists of 
the autonomic and visceral responses that return the body to a non-retching and non-vomiting state 
with or without the presence of nausea. 
For purposes of common clarification, nausea is the conscious awareness and unpleasant 
sensation of urge to vomit. It is often associated with symptoms such as salivation, swallowing, 
diaphoresis, skin pallor, tachycardia, and decreased GI activity as mentioned above. Retching is the 
spasmodic, rhythmic contractions of the respiratory muscles including the diaphragm, chest wall, and 
abdominal muscles without actual expulsion of gastric contents. Emesis, or vomiting, is the forceful 
expulsion of gastric contents caused by strong and sustained contraction of the abdominal muscles 
vomiting begins with a deep inspiration, elevation of the soft palate to occlude the nasopharynx, and 
closure of the glottis. The proximal area of the stomach relaxes and a powerful contraction of the small 
intestine forces previously ingested contents into the stomach, which then acts to dilute and buffer the 
gastric acid. Finally, contraction of the esophageal muscles pulls the stomach into the thorax, forming 
an esophageal funnel, and food is forced out of the stomach by contraction of the abdominal muscles 
against the lowered diaphragm. 
 PHARMACOLOGIST”S VIEW OF EMETIC STIMULI
Diagram of the Process of Vomiting
IV. ETIOLOGY OF POSTOPERATIVE NAUSEA AND VOMITING
Factors Contributing to the Incidence of PONV.
• Preexisting Conditions
• Age
• Gender
• History of PONV or Motion Sickness
• Preoperative Anxiety
• Obesity
• Site of Surgery/Type of Surgical Procedure
• Anesthetic Agents and Technique
• Duration of Surgery & Postoperative Conditions
• Pain & Movement
• Hypotension, hypoxemia, or hypoglycemia 
•  fasting
• Premature intake of fluids and foods.
PONV is most commonly attributed to the administration of anesthesia. This belief 
stems from the history of nausea and vomiting associated with the use of early inhalation 
anesthetic agents, such as ether. There was no significant improvement in the incidence 
of PONV until the introduction of halogenated inhalation agents in the 1960s. With 
respect to the Pathophysiology of nausea and vomiting and the ongoing research 
regarding the incidence of nausea and vomiting specific to anesthesia and surgery, 
PONV is now known to be the result of many different and interrelated factors. Thus, 
the etiology of PONV is complex and anesthesia must be considered as only one of 
many contributing factors. Several pre-existing patient factors, pre- and post-operative 
factors, and surgical and anesthesia-related factors can contribute significantly to the 
development of PONV 
Preoperative/Patient-related Factors in the Etiology of PONV
Intrinsic patient factors include age, gender, obesity, history of previous PONV or motion 
sickness, anxiety, and the presence of co-existing disease. Younger patients, particularly 6 to 16 years 
of age, appear to be more vulnerable to developing PONV, generally with an increased incidence that is 
twice that of an adult patient regardless of the anesthetic technique or surgical procedure involved. 
Various studies report an incidence of PONV ranging from 35% to 50% in childhood and early 
adolescence as compared to the 25%-30% seen in the adult surgical population 
There is an increased incidence of PONV noted in female patients after puberty, especially 
during menstruation or pregnancy, and including postmenopausal women younger than approximately 
60 years of age. This is believed to be due to an increase in serum gonadotrophin levels.. The increased 
incidence of PONV noted when surgery is performed during menstruation is highest on the 4th or 5th 
day of the menstrual cycle  which is four times greater than normal. The increased risk for experiencing 
PONV associated with obesity is due to the fact that adipose tissue acts as a reservoir for inhaled 
anesthetic agents, from where continued release of the agent into the circulation  occurs after 
discontinuation the anaesthetics... In addition, obese patients tend to have a larger residual gastric 
volume along with an increased incidence of esophageal reflux. Obese patients also have more airway 
difficulties as compared to non-obese patients and often experience increased gastric inflation as a 
result of the efforts involved in attempting to maintain an adequate airway during mask ventilation 
prior to intubation A previous history of PONV is the most significant risk factor and the best indicator 
of the potential for experiencing nausea and/or vomiting postoperatively. Generally patients with a 
history of PONV, as well as a history of motion sickness, have a three-fold to six-fold increased risk for 
experiencing PONV again. The relationship between an increased risk of PONV and a history of 
PONV or motion sickness is linked to a lower threshold for vomiting due to a well-developed reflex arc 
for vomiting. 
In view of the fact that the process of vomiting is actually a reflex, the vomiting reflex appears 
to be more highly developed in some individuals. In these situations, it is believed there is also a 
definite psychological component to the etiology of PONV and that someone with a highly developed 
vomiting reflex will experience PONV in response to minimal stimuli. In addition, quite often patients 
with a history of PONV have significant concern and increased anxiety over experiencing nausea and 
vomiting again which further enhances the potential for developing PONV. The correlation between 
increased anxiety and an increased risk for PONV is believed to be due to the release of 
catecholamines. In animal studies, the injection of epinephrine or nor epinephrine into the 3rd or 4th 
ventricle of the brain results in vomiting whereas the injection of placebo does not. Additionally, 
anxious patients are known to swallow excessive amounts of air preoperatively, which increases gastric 
volume and the risk of vomiting postoperatively due to gastric distension. 
A history of co-existing diseases  that increases the likelihood of PONV include pre-existing 
metabolic disorders, such as diabetes, uremia, electrolyte disturbance, or renal failure. Obstructions in 
the gastrointestinal or genitourinary tract, as well as disorders of the central nervous system that 
involve an increase in intracranial pressure. 
Other inherent patient characteristics increasing the susceptibility for PONV include delayed 
gastric emptying such as with pregnancy, bowel obstruction, or diabetes and increased gastric volume 
from recent oral intake or full stomach.Obviously, a patient with a full stomach is at a greater risk for 
vomiting postoperatively. Eating and digestion cause the release of gastrointestinal hormones, such as 
Serotonin, as well as distension of the stomach, which subsequently activates visceral 
mechanoreceptors, both of which stimulate the CTZ and induce vomiting..  There is an increased 
gastric volume in patients who are anxious and swallow large amounts of air preoperatively, increased 
gastric volume may also occur secondarily from gastric insufflations occurring with mask ventilation, 
especially with obese patients as mentioned previously. Additionally, inadequate airway-related 
protective mechanisms that can occur, for example with a hiatus hernia or with an anesthetized upper 
airway, further increase the risk of aspiration after experiencing PONV.
Anesthesia-related Factors in the Etiology of PONV
Anesthesia-related factors associated with PONV involve primarily the use of preanesthetic and 
anesthetic medications that are prone to stimulate the CTZ and subsequently the vomiting center. 
Inhalation agents are associated with a significantly higher incidence of PONV.. Volatile anesthetics 
alter neurotransmitter release in the area postrema and in other forebrain sites that are known to 
stimulate vomiting. They also have specific effects on the gastrointestinal tract, leading to reduced 
motility and relaxation of the gastric pylorus, which facilitates the reflux of bile. In addition, hypo 
perfusion of the GI tract secondary to the use of volatile agents may directly stimulate a visceral 
afferent pathway that leads to the release of Serotonin. Numerous peptide hormones can also be 
released by volatile anesthetics and surgery, including angiotensin II, ADH, gastrin, insulin, 
neuropeptide Y, neurotensin, somatostatin, TRH, and VIP. These hormones may indirectly induce 
vomiting through stimulation of the CTZ. The use of  inhalation agents, such as ether and 
cyclopropane, were associated with a significantly higher incidence of PONV than the currently used 
agents, presumably due to an increase in the release of endogenous catecholamines caused by the older 
gases. There are no documented differences in the rate of PONV between  halothane, Enflurane, or 
Isoflurane, however the newer agents, Desflurane and Sevoflurane, are associated with a significantly 
lower incidence of PONV due to their lower blood: gas solubility . 
The addition of nitrous oxide to volatile inhalation agents is also believed to increase the 
incidence and severity of nausea and vomiting, although this seems to be less likely in combination 
with the newer inhalation agents. There are three mechanisms attributed to the increased incidence of 
PONV in association with the use of nitrous oxide. Nitrous oxide causes stimulation of the sympathetic 
nervous system and subsequent catecholamines release along with changes in middle ear pressure that 
result in stimulation of the vestiblular system, both of which trigger nausea and vomiting. In addition, 
nitrous oxide decreases lower esophageal tone.. This subsequently leads to gastric distension that 
promotes vomiting postoperatively. Nitrous can also cause abdominal distension as a result of the 
exchange of nitrous and nitrogen in the gas that is introduced into the stomach during mask ventilation.
PONV & IV ANAESTHETICS
 PONV is less likely with the use of Propofol. Propofol is a sedative-hypnotic agent and the first 
of a new class of intravenous anesthetics called the alkyl phenols. It is associated with a significantly 
lower incidence of PONV, 1%-3%, as compared to the 10%-15% incidence with other IV anesthetic 
agents. Propofol is actually thought to possess antiemetic properties, however, there is no specific data 
describing the effects of Propofol on the CTZ. The mechanism of action of Propofol in reducing PONV 
is thought to be the result of both anti-dopamine and anti-Serotonin effects and some reports indicate 
that the incidence of PONV is significantly lower if Propofol is used alone as in a total intravenous 
anesthetic (TIVA) technique. For this reason, Propofol has become increasingly popular in outpatient 
anesthesia.
travenous (IV) anesthetic agents associated with an increased incidence of PONV include 
ketamine, Etomidate and methohexital. Ketamine is linked to an increased incidence of PONV due to 
the increased release of catecholamines. Etomidate, if given as a continuous infusion, is also associated 
with a higher incidence of vomiting postoperatively .General anesthesia  with oxygen, nitrous oxide-
opioid-muscle relaxant, is linked to a higher incidence of PONV and is believed to be due to the direct 
action of the agents used in this technique upon the CTZ. Neuromuscular blocking drugs are commonly 
used as a component of balanced anesthesia techniques, but are rarely linked to the occurrence of 
PONV. The use of high doses of opioid with certain anesthesia techniques for induction and 
maintenance of anesthesia, and for control of postoperative pain increases the risk of PONV. Increased 
vomiting is noted with IV, nasal, oral, and/or trans mucosal routes of opioid administration. Although 
opioids depress the vomiting center in a dose-dependent manner, they also increase the sensitivity of 
the vomiting center to vestiblular input and stimulate opioid receptors in the CTZ. In addition, opioids 
delay gastric emptying and increase the release of Serotonin from enterochromaffin cells in the 
intestine, which may also stimulate the CTZ. 
Opioids cause the release of anti diuretic hormone from the pituitary gland that also reduces 
gastric motility and further enhances the sensitivity of the vomiting center to emetic stimuli. Morphine 
and its derivatives  like Meperidine, Fentanyl, Alfentanil, and Sufentanil, differ in their ability to 
promote nausea and vomiting. Unlike the opioid-related side effect of respiratory depression, vomiting 
induced by opioids has not been clearly linked to an interaction between a particular opioid and a 
specific type of opioid receptor. In fact, it appears that typical analgesic doses of opioids cause little 
nausea and the nausea and vomiting that does occur with the use of opioids is often related additionally 
to patient movement, which suggests a vestibular component to opioid-induced vomiting.
General anesthesia, as opposed to regional or local anesthetic techniques, generally contributes 
to an increased incidence of PONV, although the use of regional anesthesia does not eliminate the 
potential for nausea and vomiting entirely. Recent statistics comparing the incidence of PONV 
associated with general versus epidural and spinal anesthesia are noted as 38%, 4% and 7%, 
respectively. The nausea and vomiting associated with central neuroaxial block is attributed to the 
sympathetic nervous system blockade leading to postural hypotension or the use of spinal or epidural 
opioids. 
The administration of supplemental oxygen during spinal or epidural anesthesia reduces 
symptoms of nausea and vomiting associated with a decrease in blood pressure suggesting that 
hypoxemia acts as a stimulus at the vomiting center. In addition, the incidence of nausea and vomiting 
during spinal anesthesia can be offset by the administration of atropine, suggesting that vagal 
stimulation may also trigger nausea and vomiting during this type of anesthesia nausea and vomiting 
has also been known to occur with the use of peripheral nerve blocks although the incidence is less than 
that occurring with spinal or epidural anesthesia. 
The majority of nausea and vomiting associated with any of the regional anesthetic techniques 
occurs predominantly during the intra-operative period rather than the recovery stage as with general 
anesthesia. Although the incidence is significantly lower, nausea and vomiting may also occur during 
the use of local anesthesia, which is most often combined with intravenous sedation-analgesia 
techniques. The incidence of nausea and vomiting in this surgical population varies according to the 
type of surgery performed and the sedative-analgesic medications used. 
The use of gastric suctioning intra operatively is controversial in terms of reducing versus 
inducing PONV. Gastric suction in an attempt to reduce PONV is based upon the advantage gained 
from emptying gastric contents while suctioning may also lead to unnecessary stimulation that triggers 
vomiting. There is no clear benefit of gastric suctioning in decreasing the incidence of PONV other 
than in situations of  accumulation blood in the stomach or gastric distension following certain types of 
surgery or manual mask ventilation. 
Additionally, the act of laryngeal suctioning and the presence of oral airways during emergence 
may cause gagging that induces retching and vomiting postoperatively. It is therefore, recommended 
that laryngeal and pharyngeal suctioning be performed prior to the reversal of muscle relaxants 
Surgical-related Factors in the Etiology of PONV
The physiologic effects of the surgical procedure include metabolic and endocrine changes that 
may also contribute to the occurrence of PONV. In particular, hypoxia, hypercarbia, and hypotension 
contribute to an increased likelihood of PONV.
 In addition, certain types of surgery are associated with a higher incidence of PONV The 
impairment in peristalsis and delayed gastric emptying subsequently cause an accumulation of gastric 
secretions that further stimulates visceral afferent pathways. Manipulation of the gastrointestinal tract 
also causes a release of Serotonin from enterochromaffin cells, which is then capable of direct 
stimulation of the CTZ. Surgery involving ocular stimulation or traction on the extra ocular muscles 
stimulates the afferent pathway and may alter the sensitivity of the vomiting center prior to emergence 
from general anesthesia. Middle ear surgery interferes with the vestibular apparatus with the potential 
for subsequent stimulation of the vomiting center. Procedures involving the nose and throat, such as 
septoplasty and tonsillectomy, that result in blood within the esophagus and stomach increase the 
incidence for PONV.
 Intra operative stimulation of the pharynx, including orotracheal intubation and the use of oral 
airways, may also increase the frequency of PONV. The increased risk of PONV associated with 
increased length of surgery  & anaesthesia.. One source identifies increased duration as surgery and 
anesthesia lasting more than 1 hour It is important to note that although the type of anesthesia and 
surgery is often implicated in PONV, according to one source, nausea and vomiting is a common 
complication postoperatively and very often, regardless of the type of surgery performed or the 
anesthetic technique that is utilized 
Postoperative Factors in the Etiology of PONV
Finally, postoperative considerations involved in increasing the risk of developing PONV 
include pain and the use of opioids, movement or early ambulation, hypotension, hypoxemia, 
hypoglycemia, and premature oral intake. The relationship between pain and vomiting is apparent by 
the increased incidence of vomiting after the administration of naloxane for reversal of opioid effects. 
Additionally, several studies have shown that the relief of pain is frequently associated with the relief 
of nausea. 
As mentioned previously regarding the use of opioids, sudden motion or changes in position, 
including the transport from the operating room to the post anesthesia care unit, can precipitate nausea 
and vomiting especially in patients who have received opioids suggesting that opioids sensitize the 
vestibular system to motion-induced nausea and vomiting. 
PONV is also increased in patients experiencing dizziness, most often in association with 
postural hypotension and/or hypovolemia. Postural hypotension is often an early sign of unrecognized 
hypovolemia. Patients will experience dizziness when first trying to stand up postoperatively, which 
may lead to nausea and vomiting. This is believed to be due to decreased medullary blood flow to the 
CTZ and is most often relieved with adequate hydration and/or sympathomimetics.
The timing of the initial oral intake postoperatively may also influence the incidence of PONV. 
Multiple studies have shown varied findings with some demonstrating that restriction of oral intake in 
the early postoperative period does not decrease the overall incidence of PONV but only delays its 
occurrence, while others have shown a distinct relationship between restriction of oral intake during the 
first 8 hours postoperatively and a significantly decreased incidence of PONV. Apfel et al. point out 
that although numerous factors have been associated with an increased risk for developing PONV, 
evidence based on clinical trials is available that correlates with only a few of these risk factors, namely 
female gender, history of PONV or motion sickness, non-smoking status, volatile anesthetics, nitrous 
oxide, and opioids. As a result, they conclude that PONV is caused predominantly by opioids and 
volatile anesthetics when administered to susceptible patients. Emphasis is placed on the 
recommendation that the anesthesia provider perform a preoperative patient assessment to include a 
thorough evaluation of pre-existing patient,  surgery and anesthesia-related risk factors for precipitating 
the incidence of PONV followed by the development of an appropriate anesthesia care plan that takes 
such risk factors into consideration and the implementation of appropriate therapeutic interventions as 
necessary. 
Interestingly, another factor that may contribute to the incidence of PONV is the skill level of 
the anesthesia provider in relation to the possible effects on anesthesia administration that may result in 
gastric distension from improper mask ventilation prior to induction; the incidence of hypoxia, 
hypercapnia, or hypotension intra operatively or postoperatively; instrumentation of the airway during 
laryngoscopy, suctioning, or oral airway placement; and vestibular disturbances from rough handling of 
patients during transfer and transport. It is important to note that due to the multiple and varied factors 
that may contribute to the incidence of PONV, it is recommended that an optimal study regarding 
anesthesia or surgical implications in the occurrence of PONV requires careful and precise control of 
per operative conditions in order to determine that the incidence of PONV can actually be attributed to 
a specific anesthetic or surgical intervention.
V. COMPLICATIONS OF POSTOPERATIVE NAUSEA AND VOMITING
Medical/Surgical Complications of PONV
PONV has the potential to cause further serious medical and surgical complications. Such 
complications include aspiration; dehydration and electrolyte imbalances; disruption of oral drug 
therapy; bleeding at the incision site and disruption of the surgical incision; disruption of vascular 
grafts or anastamoses; elevated blood pressure; elevated intracranial, intra ocular, and intra gastric 
pressure; tachycardia and dysrhythmias; and esophageal tears and injury. The three most significant 
complications resulting from nausea and vomiting include aspiration of gastric contents, visceral or 
wound dehiscence, and electrolyte disorders from prolonged vomiting. Laryngeal reflexes that 
generally accompany the vomiting reflex and prevent aspiration of gastric contents, are blunted in the 
presence of general anesthesia Vomiting can, therefore, result in gastric contents entering the trachea 
leading to the risk of aspiration pneumonitis 
Vomiting causes a significant increase in both intra-thoracic and intra-abdominal pressure. If 
the pharyngeal sphincter is incompletely relaxed during vomiting, the accompanying increase in intra-
thoracic pressure can cause esophageal rupture or small esophageal tears. The increase in intra-
abdominal pressure can cause stress to visceral or vascular anastamoses, as well as wound dehiscence . 
Severe and prolonged vomiting may cause significant electrolyte imbalance. The metabolic 
consequences of vomiting include the loss of gastric acid and water from the stomach; volume 
contraction alkalosis; elevated aldosterone from the resulting dehydration; and a loss of sodium, 
potassium, and bicarbonate through the kidneys in response to the alkalosis and dehydration
More importantly, there are several adverse patient consequences that result from PONV 
including accompanying pain and discomfort along with causing delays in the ability to tolerate food, 
fluids, and oral medications. Additionally, PONV considerably increases patient anxiety and 
dissatisfaction along with causing fear and anxiety over PONV in the future 
VI. ANTIEMETIC THERAPY
Antiemetic therapy in anesthesia includes both prophylactic and rescue treatment and strategies 
for per operative and postoperative management of PONV. As with most aspects of healthcare, the 
primary goal with PONV is for prevention. Certain practices, or physical measures, on the part of the 
anesthesia provider pre-, intra- and post-operatively, can often assist in reducing the occurrence or 
severity of PONV without having to rely upon the use of pharmacological measures. The first point to 
be made is that susceptible paiients for PONV may be identified  based upon the type of surgery and 
the patient’s past medical history including the presence of co-existing conditions and/or diseases and 
previous PONV or motion sickness. Thus, the initial step in the management of PONV is to assess the 
risks for the probability of experiencing PONV followed by the institution of appropriate strategies for 
managing PONV as necessary. Certain risk factors for PONV are unavoidable or unable to be 
manipulated, such as those caused by the type of surgery or certain inherent patient-related 
characteristics. However, the choice of anesthetic agents, techniques, and adjuncts to anesthesia can be 
controlled and comprise the components of the anesthesia plan that are individualized for every patient.
Strategies for Perioperative Management of PONV/Intervention Assessment Scale
As mentioned, an essential component of any strategy for the per operative management of 
PONV is obtaining a thorough history and physical examination to include the determination of 
preexisting risk factors for PONV including gender and weight, history of previous PONV, co-existing 
diseases and current medication regimens for the purpose of identifying patients who are at increased 
risk for experiencing PONV. Many practitioners utilize an intervention assessment scale for the initial 
assessment and evaluation of a given patient’s risk for experiencing PONV in order to determine the 
need for prophylactic measures and treatment through the use of such a scale, patients are given a score 
based upon specific risk factors with each risk factor worth one to three points and a total score of three 
or more points indicating the need for prophylactic antiemetic therapy
Intervention Assessment Scale
Each worth 3 points
*History of PONV
*History of motion sickness
*Gynecologic laparoscopy
*Breast reconstruction
Each worth 2 points
*Facelift surgery
*Strabismus or middle ear surgery
*Neurosurgery
*Obesity
Each worth 1 point:
*Preadolescent
*Female
*Anxiety
*Laparoscopic cholecystectomy
*Intraop /postoperative opioid
*Duration of anesthesia > 60 minutes
3 OR MORE POINTS PROPHYLACTIC ANTIEMETIC IS INDICATED
A similar means for assessing and assigning a risk score for the prediction of PONV was 
developed by Apfel et al. after studying the incidence of PONV and related risk factors and risk scores 
at different institutions. They identified four primary risk factors that comprised a simple risk factor 
scoring system, including the characteristics of female gender, prior history of PONV or motion 
sickness, nonsmoking status, and the use of intra operative and postoperative opioids, that could be 
applied broadly from one institution to another with accurate predictability for PONV. As with the 
method described above, patients are assigned a number value based upon the presence or absence of 
these four risk factors. According to their study findings, Apfel et al determined that if no risk factors 
or only one risk factor is present, the incidence of PONV varies between 10% and 21%. If two risk 
factors are present, the probability of PONV increases to between 39% and 78%. In the presence of two 
or more risk factors, an appropriate modification may be made in the anesthesia plan, including a 
change in anesthetic technique, such as the avoidance of volatile anesthetics entirely by using a total 
intravenous anesthetic technique, which is associated with significantly less PONV.A score of two or 
more indicates the need for prophylactic antiemetic treatment.
In addition to antiemetic drug therapy, other prophylactic measures can be taken to minimize 
gastric volume and acidity and to avoid regurgitation. This involves the initial determination of 
appropriate “nothing per os” (NPO) or fasting status, along with the administration of histamine 
antagonists and gastrokinetic agents as necessary. Fasting prior to receiving general anesthesia is a 
simple means for decreasing gastric volume and the risk of regurgitation and aspiration of gastric 
contents. However, because increased anxiety may stimulate gastric acid secretion and delay gastric 
emptying, the administration of anxiolytics, such as Midazolam, preoperatively may be beneficial and 
drugs that decrease lower esophageal tone, such as atropine should be avoided. The administration of 
histamine (H-2) receptor antagonists, such as ranitidine, preoperatively acts to block histamine-
mediated gastric acid secretion, which subsequently results in decreased gastric volume and increased 
pH of gastric contents. Soluble antacids, such as sodium citrate, given preoperatively are also effective 
in raising the gastric pH for as long as three hours. Metoclopramide, a benzamide, may be given 
preoperatively to stimulate the release of acetylcholine in the gut which creates a coordinated, 
peristaltic action in addition to relaxing the pylorus, increasing lower esophageal tone, and causing a 
direct depressant effect on the CTZ, all of which assists in decreasing gastric volume and minimizing 
the risks for vomiting postoperatively. There are several practices and procedures that comprise the 
strategies for intra operative management of PONV including the use of IV anesthetics such as 
Propofol; prevention of excessive stomach distension with mask ventilation; gastric suctioning prior to 
anesthesia; maintenance of adequate fluid status intra operatively; 
Prevention of hypoxia, hypercarbia, and hypotension, all of which are associated with an 
increased incidence of PONV; the use of regional anesthesia when possible, especially for high risk 
patients; application of cricoid pressure and rapid sequence induction for patients with a full stomach; 
minimizing the requirement for narcotic analgesics postoperatively through the use of local anesthetics 
and NSAID; and prophylactic antiemetic administration as necessary However, the timing of 
prophylactic antiemetic administration is controversial. With shorter surgical procedures, intravenous 
anti emetics are usually administered at the induction of anesthesia, but for longer procedures anti 
emetics are often given towards the end of the surgery for maximum benefit. Although it might seem 
logical to utilize routine prophylaxis, there are numerous anti-emetic agents and the expense of many of 
them is thought to be too high to be cost-effective and warrant their use on a routine basis. Generally, 
prophylactic antiemetic therapy is suggested only for those patients with two or more known risk 
factors for PONV. Postoperative strategies for handling PONV include adequate pain management, 
prompt removal of oral and nasal tubes that activate the gag reflex, adequate IV hydration, avoidance 
of hypotension, prevention of early and excessive movement, encouragement of slow, deep breathing, 
and early treatment with anti emetics as necessary
VI Anti Emetic Therapy
Pharmacological 
Classification
Receptor Site 
Affinity
Drugs
5-HT3 Antagonists 5-HT3 Ondansetron, Granisetron, Dolasetron, 
Tropisetron
Benzamides Dopamine Metoclopramide, Cisapride, Alizapride
Butyrophenones Dopamine Droperidol, Haloperidol, Domperidone
Phenothiazines Dopamine Promethazine, Fluphenazine, 
Perphenazine, Trifluperazine
Antihistamines Histamine Diphenhydramine, Dimenhydrinate, 
cyclizine, Meclizine hydroxyzine,
Anticholinergic 
agents
Muscarinic Hyoscine, scopolamine, Atropine
Others - Corticosteroids (Dexamethasone) 
Benzodiazepines (Lorazepam, alprazolam) 
Clonidine, Ephedrine,
Classification of Antiemetic Drugs and Receptor at Which Each Works
Many of the concepts of antiemetic therapy in surgical populations have been adopted from 
successful treatment protocols utilized in oncology in relation to chemotherapy-induced emesis. Based 
upon the understanding that vomiting is caused by the stimulation of various receptors located within 
the central nervous system and GI tract, as previously described, traditional anti emetics consist of a 
variety of drugs that block the different neurotransmitter receptors involved. 
Four major neurotransmitter receptors appear to be involved in a vomiting response, including 
dopamine, histamine (H1), cholinergic muscarinic, and Serotonin (5-HT3) receptors. Subsequently, 
these four receptors serve as the four corresponding sites of action for the various antiemetic drugs, 
whereby the blockade of one or more of these receptors by a drug is the mechanism of action involved 
in the prevention and treatment of both chemotherapy-induced and postoperative nausea and vomiting. 
Blockade of the receptor site prevents a specific neurotransmitter from working at the receptor after its 
release from the vesicles within the nerve terminal 
It is suggested that the ideal antiemetic drug would be effective at preventing and/or treating 
nausea and vomiting with minimal side effects and drug interactions. Additionally, it would be 
convenient to administer and the effects would be sufficiently long acting to last through the per 
operative period. A single antiemetic drug may work at more than one receptor, but tends to have one 
receptor at which it exhibits a predominant effect. In this regard, it is believed that no single antiemetic 
drug is 100% effective due to the multifactorial stimulus for PONV and that a multimodal approach is 
the best approach in the management of nausea and vomiting postoperatively
The various antiemetic agents utilized for the management of PONV include butyrophenones, 
benzamides, anti cholinergic, antihistamines, phenothiazines, and Serotonin antagonists . 
Conventional anti emetics are associated with clinically undesirable side effects, including 
sedation, hypotension, dry mouth, dysphoria, restlessness, and extra pyramidal symptoms. 
Butyrophenones, such as Droperidol, function as a dopamine receptor antagonist whereby antagonism 
of dopamine receptors in the CTZ provides an antiemetic effect. However, large doses of Droperidol 
have been associated with delayed emergence, drowsiness, and extra pyramidal symptoms.
The antiemetic actions of phenothiazines have been attributed to their ability to block the 
dopamine and histamine-1 receptors in the CTZ. Chlorpromazine and Promethazine are phenothiazines 
used in the prevention and treatment of PONV however, they can produce significant sedation and 
lethargy in patients recovering from general anesthesia and therefore delay recovery following 
outpatient surgery. Prochlorperazine and perphenazine are also phenothiazines noted to have a shorter 
duration of action that may require repeated dosing and are associated with a higher incidence of extra 
pyramidal side effects, ranging from restlessness to oculogyric crisis Different cholinergic muscarinic 
receptors are located in the cerebral cortex and CTZ and drugs with specific antagonistic activity at 
these receptors may assist with effective antiemetic therapy although the findings are varied. 
Scopolamine and atropine, two anti cholinergic agents that are capable of crossing the blood-brain 
barrier, may work effectively as anti emetics. However, scopolamine in particular, can produce 
undesirable side effects such as dry mouth, sedation, visual disturbances, memory dysfunction, 
dysphoria, and occasional confusion, disorientation, and hallucinations
Antihistamines, such as dimenhydrinate, hydroxyzine, and diphenhydramine, act on both the vestibular 
pathways and the vomiting center and are therefore effective in the prevention and treatment of motion 
sickness, as well as PONV associated with middle ear procedures that interfere with the vestibular 
apparatus, Metoclopramide is a benzamide that possesses both central and peripheral antiemetic 
actions. In addition to the ability to block dopamine receptors in the CTZ centrally, Metoclopramide 
increases lower esophageal tone and enhances gastric and small bowel motility peripherally, thereby 
preventing delayed gastric emptying produced by opioid analgesics and some of the volatile agents. 
Other benzamides with potent gastrokinetic action include cisapride, alizapride, and clebopride. 
Dexamethasone has also been reported as an effective antiemetic agent, especially when given in 
combination with another antiemetic drug. The mechanism of antiemetic activity related to the use of 
Dexamethasone is not fully understood but is believed to be due to either central inhibition of 
prostaglandin synthesis, a decrease in Serotonin turnover in the central nervous system. It is also 
pointed out that steroids act to release endorphins and their antiemetic activity may therefore involve a 
psychological component
The incidence of opiod-related nausea and vomiting may be minimized with the use of potent 
non-steroidal-anti-inflammatory drugs, such as ketorolac. Because ketorolac is especially effective in 
the prophylaxis of postoperative pain following ambulatory surgery, thereby reducing the amount of 
narcotic required for postoperative analgesia, it may be associated with a much lower incidence of 
PONV in the immediate postoperative period. 
The use of local anesthetics has also become increasingly popular as a means of early 
postoperative management of pain and may significantly reduce the amount of opioid analgesics 
necessary for pain management postoperatively, therefore minimizing opioid-induced nausea and 
vomiting.
Combination Antiemetic Therapy
It is important to point out that despite the lack of conclusive research results to date, it is 
becoming increasingly popular to utilize a multimodal approach, or combination of anti emetics, in the 
pharmacological management of PONV. As mentioned previously, this practice is based upon the 
complex and multifactorial etiology of PONV. It is believed that administering a drug that antagonizes 
only one of the many receptors that may be involved in the etiology of PONV is often ineffective, 
whereas using combinations of drugs with different mechanisms of action acts synergistically to 
provide an overall improved therapeutic effect. This approach is likened to the concepts of balanced 
anesthesia and balanced analgesia. The multimodal antiemetic approach takes into consideration the 
fact that each antiemetic agent may selectively block a specific receptors that may or may not be 
present in multiple anatomic sites. Combining different agents may, therefore, help to make a specific 
receptor blockade more effective and achieve a blockade in a different anatomic site or block multiple 
receptor sites. In addition, it may also serve to lessen the incidence of side effects of the anti emetics 
themselves as a result of being able to use smaller doses of each drug with combination therapy 
regimens.
 Corticosteroids, such as Dexamethasone, are the drug most commonly used in combination 
with other anti emetics for combination therapy Additionally, it is often recommended that in the event 
that an initial antiemetic or combination of anti emetics is ineffective, the preferred choice for 
additional drug therapy should involve an agent that works at a different receptor sites. Multimodal 
management of PONV, however, refers not only to a combination of pharmacological antiemetic 
agents, but to the use of multiple anti emetics in combination with numerous non pharmacological 
techniques that best avoid the incidence of PONV With regard to multimodal management of PONV 
and patients at high risk for experiencing PONV  
 Thus, further emphasis is placed on the importance of controlling PONV through minimizing or 
avoiding the preventable factors that may lead to nausea and vomiting postoperatively and utilizing 
those measures that assist in lessening PONV in association with appropriate anti emetic drug therapy
Non-Pharmacological Therapy for PONV
In addition, a variety of approaches that do not involve the use of anti emetics have been 
developed for the management of PONV, including adequate pre-, intra-, and postoperative pain relief, 
supplemental oxygen, aggressive intravenous rehydration, maintenance of blood pressure, and the use 
of acupuncture. Recently, the concept of controlled, deep breathing has also been studied for its value 
in relieving nausea postoperatively and was found to be highly effective. 
This is believed to be due to the close proximity of the respiratory and vomiting centers in the 
brain whereby the focus of the respiratory center on taking deep breaths relieves the vomiting center 
from being stimulated. A further explanation for the success of this technique is the logical assumption 
that if hypoxia acts as a stimulus to the vomiting center, increased oxygenation through deep breathing 
would have the opposite effect 
The management of pain postoperatively involves a “fine line” between maintaining patient 
comfort and triggering PONV through the use of opioids. It is not considered good practice, however, 
to withhold treatment for pain based upon a fear of opioid-induced nausea and vomiting although the 
goal should be for using the minimum amount necessary for adequate pain control. The administration 
of oxygen intra operatively and for the first 2-hour period postoperatively is consistently associated 
with a decreased incidence of PONV. As for intravenous rehydration, the administration of 20 ml/kg of 
IV fluid may decrease postoperative drowsiness, dizziness, and nausea and vomiting, although study 
findings regarding this concept have not been conclusive.10 Additional study findings have shown a 
difference in the incidence of PONV between patients receiving adequate hydration preoperatively as 
compared to those not receiving the fluids and the administration of a fluid bolus preoperatively 
associated with a decreased rate of nausea and/or vomiting regardless of antiemetic therapy. The use of 
acupuncture, that is, manual stimulation of the P-6 acupuncture point with a fine needle may result in a 
significant reduction of PONV although the findings are varied. 
In addition, studies have also been performed using the power of positive suggestion which 
have demonstrated a decrease in the incidence of PONV in patients who received positive suggestion 
pre- and intra operatively. Finally, patients recovering from anesthesia should never be near another 
patient experiencing active vomiting due to the potential for psychological, visual, olfactory, and 
auditory cerebral input that may lead to PONV in these patients
 VII.SEROTONIN ANTAGONISTS
The newest class of antiemetic is the Serotonin receptor antagonists. Serotonin receptor 
antagonists were developed through alterations of the traditional antiemetic Metoclopramide and were 
first utilized as part of medical practice in 1991 in the prevention and treatment of chemotherapy-
induced nausea and vomiting (CINV). However, there are significant differences in the etiology and 
management of CINV and PONV. CINV is mediated specifically through Serotonin receptors located 
peripherally on the vagal afferent nerve terminals and centrally in the CTZ. The use of Serotonin 
receptor antagonists has been considered a major breakthrough in the prevention of CINV and the use 
of prophylactic antiemetic therapy is a routine part of practice in association with CINV. Success of 
antiemetic therapy for CINV is generally defined as two or fewer episodes of vomiting. In contrast, the 
incidence and causes of PONV are highly variable and the use of anti emetics is not considered to be a 
routine component of anesthesia. In addition, a patient experiencing two episodes of vomiting 
postoperatively following the use of prophylactic anti emetics would be considered as having severe 
PONV and a failure of therapy. Although the mechanism of PONV is not completely understood, it is 
known that PONV often involves stimulation of the enterochromaffin cells of the GI tract by anesthetic 
agents as well as by the stress of surgery. These cells release Serotonin, which, in turn, activates 
Serotonin receptors in the CTZ and vomiting center to induce vomiting. Blockade of these receptors 
through the use of a Serotonin antagonist subsequently prevents this mechanism One source discusses 
the important role of Serotonin as a major neurotransmitter within the body. 
Serotonin, or 5-hydroxytryptamine (5-HT), is a biogenic alkyl amine synthesized from the 
dietary amino acid tryptophan and accounts for approximately 1% of the metabolism of tryptophan 
under normal homeostatic conditions. Serotonin has many different physiologic actions related to a 
wide variety of receptors and effector mechanisms within the central and peripheral nervous systems. 
Ninety percent of Serotonin is located peripherally in the enterochromaffin cells of the intestinal 
mucosa and 10% is found in the neurons of the central nervous system. Serotonin receptors are found 
peripherally in the vagal nerve terminals and centrally within the limbic system (hypothalamus), the 
cerebral cortex, and the CTZ 
Serotonin receptors have been categorized into five main subclasses of Serotonin, or 5-HT, 
receptors .The five main groups of 5-HT receptors include 5-HT1 through 5-HT5 and the 5-HT1 receptor 
is further divided into three different subtypes. The majority of the Serotonin receptors are G-protein-
coupled receptors with the exception of the 5-HT3 receptor subclass, which are ligand gated or fast ion 
channel type receptors The various 5-HT receptors are each involved in mediating different physiologic 
functional responses with the 5-HT3 receptor being the primary receptor involved in the process of 
reflex-induced vomiting. The 5-HT1 receptor is believed to be involved in smooth muscle contraction 
and relaxation, as well as having an effect on anxiety, depression, and appetite. The 5-HT2 receptors are 
also involved with smooth muscle contraction and, additionally, with vasoconstriction and platelet 
aggregation. The 5-HT3 receptors, as mentioned, are involved in the phenomenon of nausea and 
vomiting. The 5-HT4 receptors play a role in gastrointestinal motility and the precise function of the 5-
HT5 receptors is still under investigation. 
In addition to the use of 5-HT3 antagonists in antiemetic therapy, some of the other Serotonin-
related drugs are used therapeutically to treat migraines (5-HT1 receptor antagonist), vascular disorders 
(5-HT2 receptor antagonists), gastrointestinal motility disorders (5-HT4 antagonists) and behavioral 
psychopathologies (5-HT1 agonists and 5-HT2-4 antagonists). The 5-HT3 receptor was identified 
specifically as a target for anti emetics when Fozard8 observed that Metoclopramide had weak 5-HT3 
antagonistic properties in addition to its ability for blocking dopamine receptors and was, therefore, 
capable of producing a more complete antiemetic effect. Subsequent research led to the discovery of 
the complete absence of reflex-induced emesis in ferrets with the use of a selective 5-HT3 antagonist 
known as MDL 72222. This led to extensive clinical testing of selective 5-HT3 antagonists in humans 
with several selective 5-HT3 antagonists having since been developed 
The 5-HT3 antagonists are potent and highly selective competitive inhibitors of the 5-HT3 
receptor with a selectivity ratio of 100:1 for the 5-HT3 receptor as compared to the other 5-HT receptor 
types. The antiemetic action of the 5-HT3 antagonists is due to simultaneous effects at both central and 
peripheral 5-HT3 receptor sites By selectively working at the 5-HT3 receptors, 5-HT3 antagonists avoid 
the adverse effects of some of the traditional anti emetics and are associated with a significantly lower 
incidence of side effects. 5-HT3 antagonists are generally tolerated over a wide dose range and the most 
common side effects associated with their use are headache and constipation. 
Finally, 5-HT3 receptor antagonists are rapidly absorbed and cross the blood-brain barrier 
easily. Their elimination half-life varies from 3-4 hours for ondansetron and Granisetron to 7-10 hours 
for Dolasetron.Overall, the duration of the antiemetic effect of the 5-HT3 receptor antagonists appears 
to be longer than what would be expected according to the serum half-life of these drugs which is 
believed to be due to their increased affinity for the 5-HT3 receptor site. 5-HT3 antagonists are 
metabolized via various subtypes of the cytochrome P-450 system in the liver and the resulting 
metabolites are excreted mainly in the urine .
                                      GRANISETRON
It is a 5HT3 – receptor antagonist, which is 10 –15 times more potent than ondansetron.
Available as injection, tablets & Syrup form. Plasma half life : 5.3 + 3.5 hrs. But the antiemetic effect 
persists long after the drug disappears from the circulation, suggesting their continued interaction at the 
receptor level. So it can be administered effectively just once a day. It is well absorbed from the GI 
tract. Oral bio availability is 60%. Principally metabolized in the liver, a process that appears to involve 
CYP3A family of enzymes.
Protein bound : 65 + 9%
Urinary excretion : 16 + 14%
Clearance : 11 + 9 ml / min / kg.
Decreased in aged, Cirrhosis.
No change in Renal disease.
Volume of distribution 3.0 + 1.5 lit / kg.
Uses
- Post operative nausea & vomiting, Chemotherapy induced vomiting, Radiotherapy induced 
vomiting, may be useful in pruritis in Uraemic patients.
Side effects
- Generally well tolerated.
- Constipation, diarrhoea, headache, Light headedness.
Induce minor ECG changes, clinically insignificant.
 
VIII. Review of Literature
Fuji Y and Toyooka et al(1998 ) studied efficacy of Granisetron in a randomized, double
blind, placebo controlled study. A complete response, defined as no emesis and need for
another rescue antiemetic during the first 24 hour after Anaesthesia, occurred in 40%,48%,85% 
and90% of patients who had received placebo and Granisetron 20,40,80 
μgm kg-1, respectively(p<0.05);(overall Fisher’s exact probability test).
There were no clinically important adverse events. They have concluded that pre operative oral 
Granisetron, in doses 40 μgm kg-1, was effective for the prevention of post operative vomiting in 
children. 
Tanaka et al (1999) had undertaken a study to determine the effective dose of Granisetron
was effective for the prevention of post operative vomiting in children undergoing general inhalational 
anaesthesia for surgery. In their study patients were assigned to receive placebo or Granisetron at three 
different doses(20 mcg kg-1,40mcg kg-1,
100mcg kg –1) immediately after induction of anaesthesia (n=30 each).
 A complete response, defined as no emesis and no  need for another rescue antiemetic during the first 
24 h after anaesthesia, occurred in 57% with placebo,67% with Granisetron 20 mcg kg-1,
90% with granisetron40 mcg kg-1 and 90% with granisetron100 mcg kg-1respectively
(p<0.05; overall Fisher’s exact probability test). There were no clinically important adverse events. 
Results suggest that Granisetron 40 mcg kg-1 is the minimum effectivefor the prevention of post 
operative vomiting after pediatric surgery, and that increasing its dose to 100mcg kg-1 provides no 
demonstrable benefit.
A.J.  Wilson,  P.  Dieamuscl  et  al  (1996)  determined the optimal  dose of  Granisetron and to 
evaluate its safety profile.  Antiemetic prophylaxis with a single dose of Granisetron 1.0 mg or 3 mg 
resulted  in  a  significant  reduction  (P0.001)  compared  with  placebo  in  the  numbers  of  patients 
experiencing post of vomiting or who achieved total control during the post of periods 0-6 hrs & 0 – 24 
hrs.  Two high  doses  of  Granisetron  (1.0  mg  and  3.0  mg)  provided  effective  prophylaxis  against 
vomiting with 78% and 77% of patients respectively. 
Maisano et al (1995) & Ettinger et al (1996) studied antiemetic efficacy of two different doses 
of  Granisetron  (1mg & 2  mg)  for  chemotherapy induced  nausea  & vomiting.   In  their  study no 
vomiting has occurred after 24 hrs: Antiemetic efficacy is around 70% & 86.7% in the 1 mg & 2mg 
groups respectively. All the fore mentioned studies are correlated with our study. 
IX.  MATERIALS AND METHODS
The institution research committee approved the investigation and informed consent was 
obtained from all patients on whom the study was conducted.
50 Pediatric patients of ASA Status I aged between 5 – 15 yrs, who were scheduled for 
Adenotonsillectomy surgery were included in the study.  The patients were randomly divided into two 
groups A & B. Group A consisted of twenty five patients receiving a single dose of oral Granisetron 
(40 Mcg/Kg) I hour before surgery, group B consisted of 25 patients receiving a placebo.  All patients 
posted for elective Adenotonsillectomy were visited on the day before surgery.  A thorough 
preoperative assessment was done to exclude any systemic illness.  Patients with a history of motion 
sickness, H/o PONV, patients who had vomited or received antiemetics within 24 hour prior to surgery 
were excluded from the study.
Premedication
All patients were premedicated with Pentazocine 0.5mg/kg with 5mcg/kg Glycopyrrolate  30 
minutes before surgery.
Group A – given Granisetron 40 mcg/kg oral
Group B – given a placebo
Technique of Anaesthesia
All patients were given general anaesthesia with endotracheal intubation Anaesthesia induced 
with Thiopentone sodium 5mgKg-1. Sympathetic response to laryngoscopy and intubation were 
attenuated by prior administration of Lidocaine 1 - 1.5 mgKg-1. Trachea was intubated with 2 mgKg-1 
Succinylcholine. Anaesthesia was maintained with oxygen – Nitrous oxide mixture, muscle relaxant 
Vecuronium 60 – 80 mcg/Kg with small dose opioids.
Monitoring
The following were monitored in all patients
1. Pulse rate
2. Blood pressure
3. E.C.G.
At the end of surgery, the neuromuscular blockade was reversed with Neostigmine 0.05 mgKg-1 
and Glycopyrrolate 5 mcg/kg.
Postoperative period
Efficacy and safety data were collected for 24 hour postoperatively. For the first 2 hour, patients 
observed in the post Anaesthesia care unit directly. Vital signs, emetic episodes were noted.  
For the next 24 hours, a diary card was kept by the attending staff nurse who recorded the number of 
emetic episodes and the time at which the incidence took place.
The primary efficacy variable in the two studies was the number of emetic episodes.  An emetic 
episode was defined as a single vomit or retch or combinations of vomits and/or retches occurring 
within 1 minute of each other.
Complete response defined as no emetic episodes.
Major response – one emetic episode
Treatment failure – two or more emetic episodes or the receipt of a rescue antiemetic.
Rescue antiemetics were allowed at the request of the patient, upon physician determinations, or 
after two emetic episodes.
The data were recorded according to the Proforma and the results were statistically evaluated.
RESULTS
Table 1
Age distribution of the patients
Age Group
(Yrs.)
Granisetron (No: 25) Placebo (No. 25)
No. % No %
5 – 10 Yrs 13 52% 11 44%
10-15 Yrs 12 48% 14 56%
Total 25 100% 25 100%
Group A & B were comparable in age.  Mean age of Group A 10.36, Group B was 10.96.  So 
the two group are comparable in patients mean age.
Weight distribution of patients
Weight
Granisetron (No: 25)
(Group A)
Placebo (No. 25)
(Group B)
No. % No %
10 – 20 kg 1 4% 2 8%
20 – 30 kg 20 80% 11 44%
30 – 40 kg 4 16% 6 24%
40 – 50 kg - - 6 24%
Mean weight in Group A is 26.88, and in Group B is 30.04. So two group were comparable in 
patients mean weight.
TABLE 3
Emesis distribution of patients
Study
Group
Total 
No.
Pt. With POV Pt. Without POV
0-2 
hrs.
2-12 
hrs.
12 – 24 
hrs.
Total
No. of
Emesis
% No %
Group A
Granisetro
n
25 - 2 1 3 12% 22 88%
Group B
Placebo
25 2 9 3 14 56% 11 44%
 
Table 3 shows the postoperative emesis in two groups.  The table clearly shows that Granisetron 
is significantly better than placebo in preventing POV. In group A, 3 patients experienced emesis 
(12%) whereas 22 patients were emesis free (88%). In-group B 14 patients (56% )had emetic episodes 
whereas 11 patients (44%) were emesis free. The table shows that group A patients who had received 
Granisetron experienced lesser vomiting than group B who received the placebo.
The following table shows the efficacy of Granisetron in reducing the frequency of emesis in 
patients who had emesis.  88% in Granisetron had complete response.  In placebo group only 44% of 
patients had a complete response.  Major response that is only one episode of emesis was 12% in 
Granisetron group whereas it was 32% in placebo group.  Treatment failure (two or more episodes) is 
nil in Granisetron received patients, and 24% in placebo group.  The observed difference between 
group A and group B in antiemetic efficacy had compared using Z-test. The calculated value of Z 
(4.83) is very much above the table value of Z (1.96).  So the observed difference is significant P < 
0.05. This shows that administration of oral Granisetron is more effective than placebo.
Antiemetic efficacy among the study groups in reducing the frequency of occurrence of emesis
Efficacy Definition
Granisetron
(Group A)
Placebo 
(Group B)
No. % No %
Complete No emetic 22 88% 11 44%
response episode
Major 
response
One episode
3 12% 8 32%
Treatment 
failure
Two or more 
episodes
- - 6 24%
PROFORMA FOR THE STUDY
Sl. No.: Date:
Name  Age: Sex:
IP No.: Weight
Pre-operative Diagnosis:
Nature of Surgery:
Surgeon Anesthesiologist
ASA Grade:
I II
BP: PR:
RESP Rate: Premedication: Time:
Diary Card
Time of vomiting No of episodes
Technique of Anaesthesia:
Condition at the end of surgery
Post-operative nausea and vomiting
 First 2 hour: Next 10 hour. Next 12 hour.
Frequency of emesis Severity of emesis
Patient’s general assessment of
Post-operative period:
X.CONCLUSION
Anti emetics is the mainstay of therapy for POV.  The main pharmacological classes of 
drugs used in the treatment are muscarinic, dopaminergic, histaminic, or serotonergic.
In the present study, oral Granisetron (40 mcg / kg) was given orally an hour before 
surgery  in  patients  undergoing  Adenotonsillectomies,  to  evaluate  its  efficacy  in  preventing 
postoperative vomiting. Results showed that oral Granisetron is effective in preventing postoperative 
vomiting. 88% of patients were emesis free than the placebo received group.
A no.  of factors, including age,  obesity,  history of motion sickness or previous post 
operative emesis, operative procedure, anaesthetic technique & post operative pain are considered to 
increase the incidence of post operative vomiting.  However in this study there were no difference 
between  the  group  with  regard  to  patient  data,  surgical  procedure,  anesthetics  administered  & 
analgesics used after operation, and children with a history of motion sickness or previous emesis were 
excluded. Therefore, the difference in the incidence of complete response between the groups can be 
attributed to difference in the antiemetics tested.
In summary, we have found that preoperative oral Granisetron 40 mcg / kg, was effective for 
the prevention of postoperative vomiting in children undergoing Aden tonsillectomies.
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Master Chart
GRANISETRON GROUP
SL.NO NAME IP NO. AGE Wt. 
Kgs.
                 POV(Hrs)
0-2 2-12 12-24
RESPONSE
1 Tamil 974152 07/M 21 - - - CR
2 Naveen 974289 07/M 20 - - - CR
3 Kavi Barathi 974272 08/M 18 - - - CR
4 Anitha 974595 12/F 25 - - - CR
5 Kausalya 977671 08/F 20 - - - CR
6 Veeramani 975870 07/M 25 - - - CR
7 Sivasankar 975861 08/M 25 - - - CR
8 Jones 975867 11/M 26 - - - CR
9 Ajith 976392 10/M 20 - - - CR
10 Baskar 976994 06/M 20 - - - CR
11 Gayathri 977348 10/F 20 - - - CR
12 Joy 977370 10/M 20 - - - CR
13 Venkatesh 977573 08/M 20 - - - CR
14 Akila 977994 11/F 23 - - 1* MR
15 Basheer 978160 11/M 25 - - - CR
16 Reshma 978165 05/F 20 - - - CR 
17 Vetri 977990 14/M 40 - - - CR
18 Geetha 980307 15/F 40 - 1* - MR
19 Deepa 980877 16/F 20 - - - CR
20 Anusuya 981317 12/F 32 - - - CR
21 Thenmozhi 981322 11/F 27 - - - CR
22 Nasreen 982336 11/F 23 - - - CR
23 Suresh 983004 15/M 34 - - - CR
24 Nisha 983150 08/F 24 - - - CR
25 Meenatchi 975152 12/F 20 - 1* - MR
PLACEBO GROUP
Sl
No
NAME IPNO AGE WT
In 
kgs
POV (HRS)
0-2 2-12 12-24
RESPONSE
1 Baranidharan 974395 12/M 25 - 2* - TF
2 Kannaki 975865 12/F 26 - - 1 * MR
3 Monika 976284 12/F 26 - 6 * - TF
4 Manikandan 975712 15/M 45 - 1 * - MR
5 Shyam 976817 12/M 25 - 3 * - TF
6 Priya 976814 08/F 25 1 * - - MR
7 Praba 977901 13/F 40 - - - CR
8 Roopa 976996 09/F 35 - 1 * - MR
9 Nandakumar 977378 09/M 20 - - - CR
10 Shahul ameed 977530 12/M 35 - - CR
11 Kausalya 977166 10/F 26 - 2 * - TF
12 Keertika 978163 10/F 35 - - - CR
13 Sivaranjini 980453 08/F 17 - - - CR
14 Vembaiyan 980754 10/M 22 - - - CR
15 Prabakaran 981803 11/M 30 - - - CR
16 Apsara 981114 09/F 20 - - - CR
17 Parveen 982258 11/F 32 - 1 * - MR
18 Arivazhagan 985519 10/M 26 1 * - - MR
19 Praba 984081 15/M 40 - 1 * - MR
20 Kaliammal 984106 15/M 42 - 2 * - TF
21 Saravanan 985006 08/M 18 - - - CR
22 Kalistha 984495 12/F 41 - - 1 * MR
23 Karthika 984475 13/M 30 - - - CR
24 Mahadevi 985895 10/F 24 - 3 * - TF
25 Veeraragavan 973311 10/M 24 - - 1 * MR
CR—COMPLETE RESPONSE
MR—MODERATE RESPONSE
TF—TREATMENT FAILURE
*  Episode of vomiting
